{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:22:36Z","timestamp":1794716556531,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"DOI":"10.1038\/s44298-026-00200-w","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:25:34Z","timestamp":1780989934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vaccines and therapeutics for Andes hantavirus"],"prefix":"10.1038","volume":"4","author":[{"given":"Alina","family":"Tscherne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico Joel","family":"Halwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"200_CR1","unstructured":"WHO. Hantavirus. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hantavirus (WHO, 2026)."},{"key":"200_CR2","unstructured":"WHO. Hantavirus Cluster Linked to Cruise Ship Travel, Multi-country 2026. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2026-DON599 (WHO, 2026)."},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/viro.1996.0305","volume":"220","author":"N L\u00f3pez","year":"1996","unstructured":"L\u00f3pez, N., Padula, P., Rossi, C., L\u00e1zaro, M. E. & Franze-Fern\u00e1ndez, M. T. Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 220, 223\u20136 (1996).","journal-title":"Virology"},{"key":"200_CR4","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2009040","volume":"383","author":"VP Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez, V. P. et al. Super-spreaders and person-to-person transmission of andes virus in Argentina. N. Engl. J. Med. 383, 2230\u201341 (2020).","journal-title":"N. Engl. J. Med."},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/S1473-3099(23)00128-7","volume":"23","author":"PA Vial","year":"2023","unstructured":"Vial, P. A. et al. Hantavirus in humans: a review of clinical aspects and management. Lancet Infect. Dis. 23, e371\u2013e82 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.3389\/fmicb.2019.02989","volume":"10","author":"R Liu","year":"2019","unstructured":"Liu, R. et al. Vaccines and therapeutics against hantaviruses. Front. Microbiol. 10, 2989 (2019).","journal-title":"Front. Microbiol."},{"key":"200_CR7","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2025.1575112","volume":"16","author":"A Tscherne","year":"2025","unstructured":"Tscherne, A., Guardado-Calvo, P., Clark, J. J., Krause, R. & Krammer, F. Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology. Front. Immunol. 16, 2025 (2025).","journal-title":"Front. Immunol."},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1016\/j.vaccine.2020.10.035","volume":"38","author":"JY Song","year":"2020","unstructured":"Song, J. Y. et al. Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults. Vaccine 38, 8016\u201323 (2020).","journal-title":"Vaccine"},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/S0264-410X(99)00057-2","volume":"17","author":"HW Cho","year":"1999","unstructured":"Cho, H. W. & Howard, C. R. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax). Vaccine 17, 2569\u201375 (1999).","journal-title":"Vaccine"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"12781","DOI":"10.1128\/JVI.00794-11","volume":"85","author":"KS Brown","year":"2011","unstructured":"Brown, K. S., Safronetz, D., Marzi, A., Ebihara, H. & Feldmann, H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J. Virol. 85, 12781\u201391 (2011).","journal-title":"J. Virol."},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1128\/JVI.00373-09","volume":"83","author":"D Safronetz","year":"2009","unstructured":"Safronetz, D. et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus. J. Virol. 83, 7285\u201395 (2009).","journal-title":"J. Virol."},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.virol.2005.11.035","volume":"347","author":"JW Hooper","year":"2006","unstructured":"Hooper, J. W., Custer, D. M., Smith, J. & Wahl-Jensen, V. Hantaan\/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 347, 208\u201316 (2006).","journal-title":"Virology"},{"key":"200_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50774-3","volume":"15","author":"IV Kuzmin","year":"2024","unstructured":"Kuzmin, I. V. et al. Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine. Nat. Commun. 15, 6421 (2024).","journal-title":"Nat. Commun."},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1021\/acsinfecdis.5c00415","volume":"11","author":"KE Ramos","year":"2025","unstructured":"Ramos, K. E. et al. Hantavirus Gn(H) nanoparticle immunogen elicits a cross-neutralizing antibody response in Mice. ACS Infect. Dis. 11, 3061\u201370 (2025).","journal-title":"ACS Infect. Dis."},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/infdis\/jiad235","volume":"229","author":"GC Paulsen","year":"2024","unstructured":"Paulsen, G. C. et al. Safety and immunogenicity of an Andes virus DNA vaccine by needle-free injection: a randomized, controlled phase 1 study. J. Infect. Dis. 229, 30\u20138 (2024).","journal-title":"J. Infect. Dis."},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.antiviral.2007.10.012","volume":"78","author":"CB Jonsson","year":"2008","unstructured":"Jonsson, C. B., Hooper, J. & Mertz, G. Treatment of hantavirus pulmonary syndrome. Antivir. Res 78, 162\u20139 (2008).","journal-title":"Antivir. Res"},{"key":"200_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1233433","volume":"14","author":"S Afzal","year":"2023","unstructured":"Afzal, S. et al. Hantavirus: an overview and advancements in therapeutic approaches for infection. Front. Microbiol. 14, 1233433 (2023).","journal-title":"Front. Microbiol."},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s13337-014-0219-7","volume":"25","author":"ML Moreli","year":"2014","unstructured":"Moreli, M. L., Marques-Silva, A. C., Pimentel, V. A. & da Costa, V. G. Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis. Virusdisease 25, 385\u20139 (2014).","journal-title":"Virusdisease"},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1086\/425007","volume":"39","author":"GJ Mertz","year":"2004","unstructured":"Mertz, G. J. et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 39, 1307\u201313 (2004).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"200_CR20","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1128\/JVI.01405-10","volume":"84","author":"P Shrivastava-Ranjan","year":"2010","unstructured":"Shrivastava-Ranjan, P., Rollin, P. E. & Spiropoulou, C. F. Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J. Virol. 84, 11227\u201334 (2010).","journal-title":"J. Virol."},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.antiviral.2016.05.014","volume":"132","author":"BH Bird","year":"2016","unstructured":"Bird, B. H., Shrivastava-Ranjan, P., Dodd, K. A., Erickson, B. R. & Spiropoulou, C. F. Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome. Antivir. Res 132, 66\u20139 (2016).","journal-title":"Antivir. Res"},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s12325-013-0069-5","volume":"30","author":"E Grande","year":"2013","unstructured":"Grande, E. et al. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv. Ther. 30, 945\u201366 (2013).","journal-title":"Adv. Ther."},{"key":"200_CR23","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1128\/AAC.00886-13","volume":"57","author":"D Safronetz","year":"2013","unstructured":"Safronetz, D. et al. Antiviral efficacy of favipiravir against two prominent etiological agents of Hantavirus Pulmonary Syndrome. Antimicrob. Agents Chemother. 57, 4673\u201380 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"200_CR24","doi-asserted-by":"crossref","unstructured":"Garrido, J. L. et al. Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo. Sci. Transl. Med. 10, eaat6420 (2018).","DOI":"10.1126\/scitranslmed.aat6420"},{"key":"200_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109086","volume":"35","author":"TB Engdahl","year":"2021","unstructured":"Engdahl, T. B. et al. Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Rep. 35, 109086 (2021).","journal-title":"Cell Rep."},{"key":"200_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01600-24","volume":"15","author":"RL Brocato","year":"2024","unstructured":"Brocato, R. L. et al. Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source. mBio 15, e0160024 (2024).","journal-title":"mBio"},{"key":"200_CR27","doi-asserted-by":"crossref","unstructured":"Duehr, J. et al. Neutralizing monoclonal antibodies against the Gn and the Gc of the Andes virus glycoprotein spike complex protect from virus challenge in a preclinical hamster model. mBio 11, 10\u20131128 (2020).","DOI":"10.1128\/mBio.00028-20"},{"key":"200_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl5399","volume":"14","author":"E Mittler","year":"2022","unstructured":"Mittler, E. et al. Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses. Sci. Transl. Med 14, eabl5399 (2022).","journal-title":"Sci. Transl. Med"},{"key":"200_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3851\/IMP2875","volume":"20","author":"PA Vial","year":"2015","unstructured":"Vial, P. A. et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir. Ther. 20, 377\u201386 (2015).","journal-title":"Antivir. Ther."},{"key":"200_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coviro.2021.07.009","volume":"50","author":"P Guardado-Calvo","year":"2021","unstructured":"Guardado-Calvo, P. & Rey, F. A. The surface glycoproteins of hantaviruses. Curr. Opin. Virol. 50, 87\u201394 (2021).","journal-title":"Curr. Opin. Virol."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00200-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00200-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:25:45Z","timestamp":1780989945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-026-00200-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1038\/s44298-026-00200-w","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list FK as co-inventor and FK has received royalty payments from some of these patents. Mount Sinai has spun out a company, Castlevax, to develop SARS-CoV-2 vaccines. FK is co-founder and scientific advisory board member of Castlevax. FK has consulted for Merck, GSK, Gritstone, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development and with Sanofi on SARS-CoV-2 variant monitoring.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}